Ken Griffin Glycomimetics Inc Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Glycomimetics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 51,000 shares of GLYC stock, worth $13,770. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,000

Holding current value

$13,770

% of portfolio

0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.55 - $3.49 $5,171 - $7,077	2,028 Added 25.72%	9,914 $29,000
Q4 2023 Feb 14, 2024	BUY	$1.13 - $2.54 $8,911 - $20,030	7,886 New	7,886 $18,000
Q2 2023 Aug 14, 2023	BUY	$1.21 - $2.08 $2,495 - $4,288	2,062 New	2,062 $3,000
Q4 2022 Feb 14, 2023	BUY	$0.57 - $3.03 $28,683 - $152,475	50,322 New	50,322 $152,000
Q2 2022 Aug 15, 2022	SELL	$0.54 - $1.15 $930 - $1,981	-1,723 Reduced 13.76%	10,796 $6,000
Q1 2022 May 16, 2022	SELL	$1.0 - $1.58 $83,756 - $132,334	-83,756 Reduced 87.0%	12,519 $14,000
Q4 2021 Feb 14, 2022	BUY	$1.44 - $2.14 $62,079 - $92,257	43,111 Added 81.09%	96,275 $138,000
Q3 2021 Nov 15, 2021	SELL	$1.8 - $2.39 $96,571 - $128,225	-53,651 Reduced 50.23%	53,164 $117,000
Q2 2021 Aug 16, 2021	BUY	$2.16 - $3.18 $200,603 - $295,332	92,872 Added 666.08%	106,815 $247,000
Q1 2021 May 17, 2021	SELL	$2.89 - $4.22 $353,045 - $515,519	-122,161 Reduced 89.76%	13,943 $42,000
Q4 2020 Feb 16, 2021	BUY	$2.69 - $4.24 $50,103 - $78,974	18,626 Added 15.85%	136,104 $512,000
Q3 2020 Nov 16, 2020	SELL	$3.07 - $5.0 $441,241 - $718,635	-143,727 Reduced 55.02%	117,478 $360,000
Q2 2020 Aug 14, 2020	BUY	$2.06 - $3.76 $162,908 - $297,348	79,082 Added 43.42%	261,205 $982,000
Q1 2020 May 15, 2020	SELL	$1.83 - $5.41 $159,841 - $472,536	-87,345 Reduced 32.41%	182,123 $415,000
Q4 2019 Feb 14, 2020	SELL	$4.03 - $6.5 $533,761 - $860,905	-132,447 Reduced 32.95%	269,468 $1.43 Million
Q3 2019 Nov 14, 2019	BUY	$2.8 - $12.85 $67,079 - $307,847	23,957 Added 6.34%	401,915 $1.73 Million
Q2 2019 Aug 14, 2019	SELL	$10.6 - $13.12 $3.82 Million - $4.73 Million	-360,707 Reduced 48.83%	377,958 $4.51 Million
Q1 2019 May 15, 2019	SELL	$9.96 - $13.44 $578,496 - $780,622	-58,082 Reduced 7.29%	738,665 $0
Q4 2018 Feb 14, 2019	SELL	$8.47 - $14.71 $451,637 - $784,366	-53,322 Reduced 6.27%	796,747 $7.55 Million
Q3 2018 Nov 13, 2018	SELL	$13.7 - $17.12 $8.26 Million - $10.3 Million	-603,008 Reduced 41.5%	850,069 $0
Q2 2018 Aug 10, 2018	BUY	$14.63 - $19.19 $4.25 Million - $5.58 Million	290,524 Added 24.99%	1,453,077 $0
Q1 2018 May 11, 2018	BUY	$16.06 - $25.35 $12 Million - $19 Million	749,434 Added 181.41%	1,162,553 $18.9 Million
Q4 2017 Feb 09, 2018	BUY	$10.51 - $17.22 $3.73 Million - $6.11 Million	354,697 Added 607.13%	413,119 $6.94 Million
Q3 2017 Nov 09, 2017	BUY	$10.14 - $14.85 $592,399 - $867,566	58,422	58,422 $817,000

Others Institutions Holding GLYC

# of Institutions

Shares Held

30.3M

Call Options Held

51K

Put Options Held

1.4K

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $14.2M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account